MCK

McKesson (MCK) closed at $1,030.12, up 1.95%, outperforming the S&P 500's 0.28% gain. The prescription drug distributor has gained 13.98% over the past month.

Analysts project Q4 2026 earnings of $10.69 per share (8.42% YoY growth) and full-year earnings of $44.71 per share (14.32% YoY growth). MCK trades at a Forward P/E of 22.6, above its industry average of 17.17, and holds a Zacks Rank #3 (Hold) rating.

McKesson (MCK) closed at $976.57, up 1.53% and outperforming the S&P 500's 1.11% decline. The prescription drug distributor has gained 6.93% over the past month.

Analysts expect November 2026 earnings of $10.72 per share (8.72% YoY growth) and full-year earnings of $44.73 per share (14.37% growth). McKesson holds a Zacks Rank #2 (Buy) rating with a Forward P/E of 21.5, trading at a premium to its industry average of 17.49.

McKesson (MCK), a leading North American pharmaceutical distributor, receives a #3 (Hold) rating from Zacks with a VGM Score of A. The stock shows strong momentum with a B score and 5.6% gains over four weeks. Analysts have raised fiscal 2027 earnings estimates by $0.18 to $44.73 per share, with GLP-1 medications driving growth at nearly $41 billion in FY25 revenues.